You can buy or sell CytRx and other stocks, options, ETFs, and crypto commission-free!
CytRx Corporation Common Stock, also called CytRx, is a biopharmaceutical research and development company, which engages in the discovery, research, and clinical development of novel anti-cancer drug candidates. It focuses on developing the Linker Activated Drug Release (LADR) technology platform, a discovery engine to help create a pipeline of anti-cancer molecules that will avoid unacceptable systemic toxicity while delivering highly potent agents directly to the tumor. Read More The company was founded on February 28, 1985 and is headquartered in Los Angeles, CA.
Los Angeles, California
52 Week High
52 Week Low
Research And Development
Yahoo FinanceMay 15
CytRx: 1Q Earnings Snapshot
LOS ANGELES (AP) _ CytRx Corp. (CYTR) on Wednesday reported a loss of $1.4 million in its first quarter. The Los Angeles-based company said it had a loss of 4 cents per share. Losses, adjusted to account for discontinued operations, were 5 cents per share. The company's shares closed at 52 cents. A year ago, they were trading at $1.32. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on CYTR at h...
Yahoo FinanceMay 15
CytRx Corporation Reports First Quarter 2019 Financial Results
Out-licensed Assets Aldoxorubicin and Arimoclomol Rapidly Advancing into Multiple Indications of High Unmet Need CytRx Stands to Receive Significant Future Milestone Payments and Royalties from Licensing Agreements LOS ANGELES, May 15, 2019 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced financial results for the first quarter ended March 31, 2019, and provided an overview of recent accomplishments and plans for its r...
Yahoo FinanceMay 8
CytRx Corporation Highlights Patent Issued for Use of Aldoxorubicin in the Treatment of Brain Cancer
The Patent Covers the Use of Aldoxorubicin Intravenously, Intra-Arterially or Intramuscularly for the Treatment of Brain Cancer LOS ANGELES, May 8, 2019 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted that it has been issued a patent from the U.S. Patent and Trademark Office (USPTO) covering the use of aldoxorubicin intravenously, intra-arterially or intramuscularly for the treatment of brain cancer, which patent was...
-$0.06 per share
-$0.05 per share